HIGHLIGHTS
SUMMARY
Meningiomas are the most common primary intracranial neoplasms and are usually treated by microsurgical resection and/or radiation therapy. Although the vast majority of meningiomas are characterized by benign biological behavior and therefore correspond to WHO grade I, about 20% of the tumors display frequent recurrences (50-90%) and increased mortality and are therefore classified as grade II and III lesions. Treatment of tumors refractory to microsurgery and irradiation is a key challenge during neuro-oncological care for meningioma patients, and further, e_g, chemotherapeutical options are urgently needed. Decitabine (DCT, 5-aza-2`-deoxycytidine . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.